Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population-Reference-Cited by-同舟云学术

Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population

Published:2010-03-19 Issue:5 Volume:51 Page:926-930
ISSN:0013-9580
Container-title:Epilepsia
language:en
Short-container-title:

Author:

Tassaneeyakul Wichittra,Tiamkao Somsak,Jantararoungtong Thawinee,Chen Pei,Lin Shu-Yi,Chen Wei-Hsuan,Konyoung Parinya,Khunarkornsiri Usanee,Auvichayapat Narong,Pavakul Kasemsin,Kulkantrakorn Kongkiat,Choonhakarn Charoen,Phonhiamhan Siranun,Piyatrakul Namfon,Aungaree Thiti,Pongpakdee Sunsanee,Yodnopaglaw Praphan

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1528-1167.2010.02533.x/fullpdf

Reference16 articles.

1. Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster;Alfirevic;Pharmacogenet Genomics,2006

2. Medical genetics: a marker for Stevens-Johnson syndrome;Chung;Nature,2004

3. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations;Ferrell;Pharmacogenomics,2008

4. Noncovalent interactions of drugs with immune receptors may mediate drug-induced hypersensitivity reactions;Gerber;AAPS J,2006

Cited by 250 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stevens–Johnson syndrome and toxic epidermal necrolysis: Updates in pathophysiology and management;Chinese Medical Journal;2024-09-05

2. Prevalence and clinical outcomes of off‐label gabapentin prescription in neuropathic orofacial pain;Oral Surgery;2024-08-27

3. Economic Evaluation of HLA-B*15:02 Genotyping for Asian Australian Patients With Epilepsy;JAMA Dermatology;2024-06-01

4. Phenomic landscape and pharmacogenomic implications for HLA region in a Taiwan Han Chinese population;Biomarker Research;2024-05-03

5. Human Leukocyte Antigens and Sulfamethoxazole/Cotrimoxazole–Induced Severe Cutaneous Adverse Reactions;JAMA Dermatology;2024-05-01